Journal of Parkinson’s Disease Achieves Significant Impact Factor Increase
July 7, 2020
Amsterdam, NL – The Journal of Parkinson's Disease (JPD) and its publisher IOS Press are proud to announce that JPD's Journal Impact Factor has increased to 5.178 according to Clarivate's 2020 edition of the Web of Science Journal Citation Reports™ (JCR). This represents an impressive 40% increase from last year.
According to the JCR, JPD now ranks 50th out of 271 journals in the competitive Neurosciences category. This positions the journal in top quartile of titles, up from 89th out of 267 (second quartile) last year. The annual JCR release enables the research and library communities to evaluate the world’s high-quality academic journals using a range of journal citation indicators, descriptive data and visualizations.
Editors-in-Chief Patrik Brundin, MD, PhD, and Bastiaan Bloem, MD, PhD, commented: “We are extremely pleased to have quantitative evidence of the high regard in which JPD is held by researchers and clinicians in the global PD community and the extent to which JPD’s articles are cited throughout the medical and scientific literature. Our ongoing commitment to the publication of the highest quality content and the dedication of the entire editorial board, contributing authors, referees and our publisher, IOS Press, have certainly contributed to the continuing growth and success of the journal.”
In addition to coverage in Web of Science, JPD is included in PubMed, Medline and Scopus, among other prominent abstracting and indexing services. JPD’s current CiteScore (released June 2020), a metric powered by Scopus that provides an indication of research impact, has also improved this year, rising from 6.1 to 6.6 and ranking the journal as 51st out of 348 journals in the Neurology (Clinical) subject category and 26th out of 84 titles in Cellular and Molecular Neuroscience.
Dr. Brundin and Dr. Bloem would also like to acknowledge the many contributions of Editor-in-Chief Emeritus J. William Langston, MD, Stanford University, whose efforts helped establish the journal as the influential, positive force it is in the field today.
Patrik Brundin is director of the Center for Neurodegenerative Science and Jay Van Andel Endowed Chair at Van Andel Research Institute in Grand Rapids, MI, USA. Bastiaan Bloem is a consultant neurologist and the director of the Center of Expertise for Parkinson & Movement Disorders at the Radboud University Medical Centre, Nijmegen, The Netherlands, and holds the position of professor of neurology with a special interest in movement disorders.
NOTES FOR EDITORS
About Journal of Parkinson’s Disease
Celebrating its 10th anniversary in 2020, the Journal of Parkinson’s Disease (JPD) is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment of Parkinson’s disease. The journal publishes research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and an affordable open access option. journalofparkinsonsdisease.com
About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 80 international peer-reviewed journals and about 75 book titles each year on subjects ranging from computer science, artificial intelligence, and engineering to medicine, neuroscience, and cancer research. iospress.com